Page 100 - Read Online

Page 78 Owusu Obeng et al. J Transl Genet Genom 2021;5:64-79 I http://dx.doi.org/10.20517/jtgg.2020.52

35. Chanfreau-Coffinier C, Hull LE, Lynch JA, et al. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs
Prescribed Among US Veterans Health Administration Pharmacy Users. JAMA Netw Open 2019;2:e195345.
36. Cecchin E, Roncato R, Guchelaar HJ, Toffoli G; Ubiquitous Pharmacogenomics Consortium. Ubiquitous Pharmacogenomics (U-PGx):
The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice. Curr Pharm
Biotechnol 2017;18:204-9.
37. L Rogers S, Keeling NJ, Giri J, et al. PARC report: a health-systems focus on reimbursement and patient access to pharmacogenomics
testing. Pharmacogenomics 2020;21:785-96.
38. Ji Y, Skierka JM, Blommel JH, et al. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five
Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade. J Mol
Diagn 2016;18:438-45.
39. Mostafa S, Kirkpatrick CMJ, Byron K, Sheffield L. An analysis of allele, genotype and phenotype frequencies, actionable
pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and
VKORC1 genes. J Neural Transm (Vienna) 2019;126:5-18.
40. Cavallari LH, Johnson JA. A case for genotype-guided pain management. Pharmacogenomics 2019;20:705-8.
41. Cicali EJ, Blake K, Gong Y, et al. Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A
Pilot, Randomized, Multisite Pragmatic Trial. Clin Transl Sci 2019;12:172-9.
42. Volpi S, Bult CJ, Chisholm RL, et al. Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US
Programs and Projects. Clin Pharmacol Ther 2018;103:778-86.
43. Owusu-Obeng A, Weitzel KW, Hatton RC, et al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics.
Pharmacotherapy 2014;34:1102-12.
44. Johnson JA. Pharmacists should jump onto the clinical pharmacogenetics train. Am J Health Syst Pharm 2016;73:2013-6.
45. Weitzel KW, Elsey AR, Langaee TY, et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med
Genet C Semin Med Genet 2014;166C:56-67.
46. Rafi I, Crinson I, Dawes M, Rafi D, Pirmohamed M, Walter FM. The implementation of pharmacogenomics into UK general practice: a
qualitative study exploring barriers, challenges and opportunities. J Community Genet 2020;11:269-77.
47. Caudle KE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Relling MV, Klein TE. Evidence and resources to implement pharmacogenetic
knowledge for precision medicine. Am J Health Syst Pharm 2016;73:1977-85.
48. Bank PCD, Caudle KE, Swen JJ, et al. Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and
the Dutch Pharmacogenetics Working Group. Clin Pharmacol Ther 2018;103:599-618.
49. Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from
the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med 2017;19:215-23.
50. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus
Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin
Transl Sci 2020;13:116-24.
51. Ross CJ, Visscher H, Sistonen J, et al; CPNDS Consortium. The Canadian Pharmacogenomics Network for Drug Safety: a model for
safety pharmacology. Thyroid 2010;20:681-7.
52. Gaedigk A, Dinh JC, Jeong H, Prasad B, Leeder JS. Ten Years’ Experience with the CYP2D6 Activity Score: A Perspective on Future
Investigations to Improve Clinical Predictions for Precision Therapeutics. J Pers Med 2018;8:15.
53. Angiolillo DJ, Rollini F, Storey RF, et al. International Expert Consensus on Switching Platelet P2Y 12 Receptor-Inhibiting Therapies.
Circulation 2017;136:1955-75.
54. Shah RR, Smith RL. Addressing phenoconversion: the Achilles’ heel of personalized medicine. Br J Clin Pharmacol 2015;79:222-40.
55. Bahar MA, Setiawan D, Hak E, Wilffert B. Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic
review on CYP2C9, CYP2C19 and CYP2D6. Pharmacogenomics 2017;18:701-39.
56. Storelli F, Matthey A, Lenglet S, Thomas A, Desmeules J, Daali Y. Impact of CYP2D6 Functional Allelic Variations on Phenoconversion
and Drug-Drug Interactions. Clin Pharmacol Ther 2018;104:148-57.
57. Hicks JK, Bishop JR, Sangkuhl K, et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics
Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake
Inhibitors. Clin Pharmacol Ther 2015;98:127-34.
58. Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of
achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002;22:1001-6.
59. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information
into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83:234-42.
60. Crews KR, Gaedigk A, Dunnenberger HM, et al; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics
Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther
2014;95:376-82.
61. Borges S, Desta Z, Jin Y, et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug
exposure among breast cancer patients. J Clin Pharmacol 2010;50:450-8.
62. Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 2008;118:250-67.
63. Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to
CYP2C19 genotypes. Br J Clin Pharmacol 2010;70:383-92.